Patients with thrombocytosis should be tested for cancers, team says

Platelets (blue) surrounded
by red blood cells
Image by Graham Beards
Researchers have found evidence to suggest that thrombocytosis is a strong predictor of cancer, particularly lung and colorectal cancer. The team therefore believes patients with thrombocytosis should be evaluated for an underlying malignancy, as such investigation could speed up cancer diagnosis and save lives. “We know that early diagnosis is absolutely key in whether people survive cancer,” said Sarah Bailey, PhD, of the University of Exeter Medical School in the UK. [Read Article]

PK-guided prophylaxis reduces dosing, still prevents bleeds

Antihemophilic factor
Personalized prophylaxis with a recombinant factor VIII product allowed for reduced dosing while still providing protection from bleeds in a small study of patients with severe hemophilia A. Researchers tested pharmacokinetic (PK)-guided prophylaxis with simoctocog alfa in previously treated patients with severe hemophilia A. The approach reduced the dose administered and increased the dosing interval compared to standard prophylaxis, without compromising protection from bleeds. Researchers reported these results in the journal Haemophilia. [Read Article]

FDA approves new formulation of deferasirox

Sachets of Jadenu Sprinkle
granules (deferasirox)
Photo courtesy of Novartis
The US Food and Drug Administration (FDA) has approved a new formulation of deferasirox known as Jadenu Sprinkle granules. The granules are approved for use in the same population as Jadenu film-coated tablets. Both formulations of Jadenu have accelerated approval from the FDA for the treatment of chronic iron overload due to blood transfusions in patients age 2 and older. The formulations also have accelerated FDA approval for the treatment of chronic iron overload in patients age 10 and older with non-transfusion-dependent-thalassemia and a liver iron concentration of at least 5 mg Fe per gram of dry weight . . . [Read Article]